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Edited by Michael R. BubbAbstract Disabled-2 (DAB2) is an adaptor protein implicated
in signal transduction pathways and in protein traﬃc regulation.
Here, we show that DAB2 is highly expressed in human endothe-
lial cells. DAB2 silencing in endothelial cells by lentiviral-medi-
ated small hairpin RNA expression aﬀects cell migration and
diﬀerentiation into capillary-like structures while increasing cell
proliferation and viability. DAB2 knockdown causes activation
of the Src-FAK signal pathway, extracellular-signal regulated
kinase and c-Jun NH2-terminal kinase activation, and inhibition
of p38 phosphorylation. In DAB2 silenced endothelial cells,
pharmacological inhibition of Src with its speciﬁc inhibitor
PP2 abolishes focal adhesion kinase activation and restores dif-
ferentiation of endothelial cells. These results suggest that
DAB2, via Src and focal adhesion signaling, plays a role in hu-
man endothelial cell function.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Focal adhesion kinase; Src; Mitogen-activated protein kinase1. Introduction
Dab2 (also known as p96 and DOC-2) is an adaptor protein
implicated in growth factor signaling [1,2], endocytosis [3], cell
adhesive function [4,5], and hematopoietic cell diﬀerentiation
[6]. Like other adaptor proteins, Dab2 contains protein-bind-
ing domains and phosphorylation sites, and lacks catalytic
domains [7]. Dab2 contains an amino-terminal phosphotyro-
sine-binding (PTB) domain and a carboxy-terminal proline-
rich domain (PRD), which have been shown to associate with
the low-density lipoprotein receptor [3,8], myosin VI [9], the
integrin b subunits [10–12], TAK1 [5], Grb2 [1,2], c-Src [13],
Smad2/3 [14], DIP1/2 [15], Dvl-3 [16], and axin [17]. These
interactions have been shown to modulate protein traﬃcking,
cytoskeleton organization, cell adhesion and migration, and
cell signaling of various receptor protein–tyrosine kinases.Abbreviations: DAB2, Disabled-2; HUVEC, human umbilical vein
endothelial cells; MAPK, mitogen-activated protein kinase; ERK,
extracellular-signal regulated kinase; FAK, focal adhesion kinase;
JNK, c-Jun NH2-terminal kinase
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doi:10.1016/j.febslet.2008.06.025Dab2 thus plays a pivotal role in the control of cellular homeo-
stasis.
Dab2 knock-out mice are embryonic lethal for defective vis-
ceral endodermal cell organization [18], and Dab2 regulates
both lipoprotein traﬃcking [19] and generation and mainte-
nance of epithelial polarity [20]. Although there is no evidence
that Dab2 plays a role in angiogenesis in the mouse [18,19] or
humans [21], in zebraﬁsh it has been shown that Dab2 expres-
sion is restricted to the presumptive endothelial cells of the
forming vasculature of the trunk [22] and in Xenopus early
development Dab2 is expressed in the blood vessels and regu-
lates angiogenesis acting as a speciﬁc mediator of activin-like
signaling pathway for VEGF induction [23].
In this report, we show that DAB2 is expressed in mouse
endothelium and in human umbilical vein endothelial cells
(HUVEC), suggesting that DAB2 plays a role in mammalian
angiogenesis. As endothelial cells play a pivotal role during
angiogenesis and function as both transducer and eﬀectors of
local environmental signals [24], we investigated the function
of DAB2 in human endothelial cells. In HUVEC, DAB2
silencing impaired migration and endothelial cell diﬀerentia-
tion into capillary-like structures. Moreover, DAB2 silencing
led to the activation of Src-FAK signaling and the modulation
of mitogen-activated protein kinase (MAPK) phosphoryla-
tion. Together our data demonstrate a role of DAB2 in the
control of endothelial cell function by modulating Src activity.2. Materials and methods
2.1. Immunoﬂuorescence microscopy
For histological analysis, SWISS mice were killed and portions of
tail were dissected and frozen in liquid nitrogen. Umbilical cords col-
lected from uncomplicated pregnancies were dissected and frozen in
liquid nitrogen. Cryostat sections (20 lm) were cut and ﬁxed in 3%
paraformaldehyde for 20 min at room temperature. HUVEC were iso-
lated from umbilical cords and cultured in M199 culture medium con-
taining 20% fetal bovine serum and growth supplements. Cells were
seeded on glass coverslips and ﬁxed in 3% paraformaldehyde. Speci-
mens were treated as previously described [25]. The primary antibod-
ies used were: rabbit anti-von Willebrand factor (Dako), rat anti-
CD31 (PharMingen), mouse anti-Dab2/p96 (Transduction Laborato-
ries), rabbit anti-phospho-Y925 FAK, rabbit anti-Src (32G6), and
rabbit anti-phospho-Y416 Src (Cell Signaling). Fluorescent images
were captured using a Leica TCS SP2 laser scanning confocal micro-
scope.
2.2. DAB2 RNA interference
Small hairpin (shRNA) cassette was cloned, and the recombinant
lentiviruses were produced as previously described [25]. Brieﬂy, oligo-
nucleotides coding for human DAB2 (GeneBank accession number
NM_001343) and unrelated (synthetic construct, GeneBank accessionblished by Elsevier B.V. All rights reserved.
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5 0-GTCCATACAGAATGGCGTAAA-3 0 (DAB2, clone 22), 5 0-
GTATCTGAAAGAGAACAGAAC-30 (DAB2, clone 47), and 5 0-
GCCACAAGTTCAGCGTGTC-3 0 (unrelated) followed by a spacer,
their reverse complementary strand, and an RNA polymerase III tran-
scriptional stop signal. The complementary oligonucleotides were
phosphorylated, annealed, and cloned into the lentiviral vector.
HEK293 cells were transiently transfected using Lipofectamine
2000 reagent (Invitrogen) following the manufacturers instructions.
Recombinant lentiviruses were harvested, concentrated by ultracentri-
fugation, and used for infection experiments. Vector infectivity was
evaluated titrating shRNA-expressing virus by quantitative RT-PCR
of a common lentiviral genome region when compared with the unre-
lated shRNA vector.
2.3. Cell viability, proliferation, and adhesion assays
The eﬀect of DAB2 silencing on HUVEC viability was evaluated by
spectrophotometric measurement of the mitochondrial dehydrogenase
activity, apoptosis was assessed by annexin V/propidium iodide dou-
ble-staining assay, and cell proliferation was evaluated by thymidine
incorporation as described in Supplementary methods online.
Adhesion assay was performed in plates coated with 1% gelatin in
PBS. Infected HUVEC were grown in complete medium, trypsinized,
plated into coated wells (2 · 104 cell/well), and incubated at 37 C
(5% CO2). At diﬀerent time points cells were washed and the number
of adherent cells was determined by MTT assay using linear curves
plotted on known amounts of cells.
2.4. Tube formation and migration assays
Formation of capillary-like tube structures was examined on Matri-
gel (growth factor reduced, BD Biosciences). Matrigel (0.1 ml) was
polymerized on 24-well plates and 2 · 104 cells were seeded in com-
plete growth medium. The Src family tyrosine kinase inhibitor PP2
was purchased from Calbiochem. For PP2 treatment, cells were grown
for 6 h in complete medium in the presence of 2 lM PP2 and then
seeded in Matrigel containing 2 lM PP2. After 20 h, images of tube
formation were captured using an inverted microscope (Leica DMIL)
equipped with a Nikon DXM1200 digital camera. Chemotaxis analy-
sis was performed as previously described with Boyden transwell
chambers [26].
2.5. Immunoprecipitation and immunoblotting analyses
Immunoprecipitation and immunoblotting analyses were performed
as previously described [25]. Cultures were starved in serum-free M199
medium containing 0.25% bovine serum albumin for 16–20 h. Cell
lysates were immunoprecipitated with anti-Src (32G6), anti-Src-aga-
rose (clone GD11, Upstate), or anti-phospho-Y925 FAK antibodies.
To improve the detection of immunoprecipitated proteins we used
ExactaCruz reagents (Santa Cruz Biotechnology). In immunoblot-
ting the following primary antibodies were used: anti-Src (32G6);
anti-p38; anti-phospho-p38 (T180/Y182); anti-p44/42 MAPK; anti-
phospho-p44/42 MAPK (T202/Y204); anti-SAPK/JNK; anti-phos-
pho-SAPK/JNK (T183/Y185) (Cell Signaling); anti-b-tubulin (D10),
anti-FAK (Santa Cruz Biotechnology); anti-b-actin (Sigma–Aldrich).Fig. 1. DAB2 localization in endothelial tissues. (A) Section of
endothelial vessels through mouse tail stained by immunoﬂuorescence
using anti-CD31 and anti-DAB2 antibodies. Scale bar, 45 lm. (B) Vein
section through human umbilical cord stained by immunoﬂuorescence
using anti-von Willebrand factor (von Will) and anti-DAB2 antibod-
ies. Scale bar, 150 lm. The merge of the double staining (merge) and
the transmitted light interference contrast (TLic) of the same cross-
sections are shown. (C) HUVEC were grown in complete medium and
analyzed by immunoﬂuorescence using anti-DAB2 antibodies. TLic,
transmitted light interference contrast. Scale bar, 11 lm.3. Results
3.1. DAB2 is expressed in vascular tissues
To investigate DAB2 expression in mammalian endothelium,
we ﬁrst performed on mouse tail double immunohistochemical
staining for Dab2 and CD31, a marker of endothelial cells. The
analysis of vessel sections revealed overlapping of Dab2 and
CD31 signals, demonstrating that Dab2 is expressed in mouse
endothelial tissues (Fig. 1A). To determine whether DAB2 is
expressed on human endothelium, we analyzed cross-sections
and primary endothelial cells from the umbilical vein by immu-
nostaining. The analyses by indirect immunoﬂuorescence
revealed that in the umbilical vein endothelium DAB2 co-local-
izes with the von Willebrand factor, a marker of endothelial
cells (Fig. 1B), and in HUVEC endogenous DAB2 was local-
ized in numerous discrete spots as previously described for
other cell types (Fig. 1C) [3,8].
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angiogenesis
To elucidate the role of DAB2 in human endothelial cells we
adopted the RNAi technology approach. Western blot analysis
of DAB2 in HUVEC showed that this protein is constitutively
expressed in these cells and its level is not modulated by star-
vation or VEGF treatment (Fig. 2A). To silence DAB2 we gen-
erated two lentiviral constructs (clones 22 and 47) expressing
two independent DAB2 shRNAs. HUVEC infected with len-
tiviruses expressing either DAB2 shRNA showed a reduced
DAB2 protein expression while no DAB2 reduction was ob-
served upon infection with a lentivirus expressing an unrelated
shRNA (Fig. 2B). In the adult, endothelial cells are normally
quiescent, but in response to appropriate stimuli (injury and
disease), they become activated and are co-ordinately involved
in the process of proliferation, migration, and diﬀerentiation.
In order to determine the eﬀect of DAB2 silencing on angio-
genesis, we investigated the ability of HUVEC to form capil-
lary-like structures when cultured on Matrigel, which is a75
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Fig. 2. DAB2 silencing aﬀects in vitro adhesion, migration, and tube format
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plotted on known amounts of cells. Results were expressed as means ± S.E.process mimicking sprouting and tube formation during angi-
ogenesis in vivo. Transduction of HUVEC before suspension
in Matrigel with lentiviruses carrying the control shRNA did
not aﬀected tubulogenesis (Fig. 2C). If, however, cells were in-
fected with lentiviruses carrying DAB2 shRNA, tubulogenesis
was strongly impaired, since DAB2 silenced cells produced few
and broken tubes unable to connect to each other. As both
migration and adhesion are critical for angiogenesis, we per-
formed in vitro migration and adhesion assays to investigate
the role of DAB2 in these processes. Analysis of cell migration
using the Boyden chamber assay showed a signiﬁcant reduc-
tion of migration of DAB2 knockdown endothelial cells com-
pared with control cells (Fig. 2D). Similar results were
obtained through wound closure assays (data not shown). Cell
attachment assays were performed on culture plates coated
with gelatin. HUVEC silenced for DAB2 showed a signiﬁcant
increased adhesion to the matrix compared to cells expressing
the control shRNA (Fig. 2E). Taken together these results sug-
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cells into vessel structures.
3.3. In human endothelial cells, DAB2 silencing aﬀects Src-FAK
signaling
A possible candidate for DAB2-dependent activity is Src,
since Src is a tyrosine kinase located at focal adhesions involved
in cell motility, adhesion, proliferation, and survival. In tumour
cells DAB2 is known to be a negative regulator of Src activa-
tion via binding to its SH3 domain [13,27]. Accordingly, we
found that in HUVEC DAB2 co-immunoprecipitated with
Src (Fig. 3A). To investigate the eﬀect of DAB2 knockdown
on endogenous unstimulated Src activity in endothelial cells,
we performed immunoprecipitation analyses from serum-de-
pleted cells. As shown in Fig. 3B, Src phosphorylation at
Y416, a protein modiﬁcation that is closely correlated with
the active form of Src kinase, was signiﬁcantly increased in
DAB2 silenced cells respect to control endothelial cells. More-
over, immunoﬂuorescence analyses showed that Src phosphor-
ylation at Y416 was associated with peripheral adhesions and it
was strongly increased in DAB2 silenced cells compared to
DAB2 expressing cells (Fig. 3C). Emerging evidence supports
the important role for FAK in the endothelial cell motility re-
sponse [28]. Since in cancer cells speciﬁc Src-dependent phos-C
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Fig. 3. DAB2 knockdown aﬀects c-Src activation in human endothe-
lial cells. (A) Cell extracts from serum-induced endothelial cells were
immunoprecipitated with anti-Src antibodies. The immunoprecipita-
tion was analyzed by Western blotting with anti-DAB2 and anti-Src
antibodies. As control a non-correlated antibody was used (NC). To
conﬁrm equal loading, whole cell lysates (load) were analyzed by
Western blotting with anti-DAB2 and anti-Src antibodies. (B)
HUVEC were infected with a lentiviral vector expressing unrelated
(unr) or DAB2 shRNA clone 22 (D22) and clone 47 (D47). Cell
extracts from serum-starved cells were immunoprecipitated with anti-
Src antibodies. The immunoprecipitation was analyzed by Western
blotting with anti-phospho-Y416 Src antibodies (P-Y416). To conﬁrm
equal loading, whole cell lysates were analyzed by Western blotting
with anti-Src and anti-b-actin antibodies. (C) Infected HUVEC as in B
were mixed and plated onto the same glass coverslip to obtain
microscope ﬁelds containing DAB2 expressing and not-expressing
cells. Cells were grown in serum-deprived medium for 16 h and
analyzed by immunoﬂuorescence using anti-DAB2 (DAB2) and anti-
phospho-Y416 Src (P-Y416 Src) antibodies. A representative micro-
scope ﬁeld is shown and a white line indicates cell boundary. TLic,
transmitted light interference contrast of stained cells. Scale bar,
16 lm.phorylation of FAK Y925 is associated with the ability of
cells to dynamically regulate cell adhesions [29], we next inves-
tigated the phosphorylation state of FAK in endothelial cells
silenced for DAB2. We performed immunoprecipitation analy-
ses of cell extracts from quiescent cells by using anti-Y925 FAK
antibodies. As shown in Fig. 4A (lanes 1–3), DAB2 knockdown
determined a signiﬁcant increase of FAK phosphorylation at
Y925 respect to control endothelial cells. Double-staining with
both anti-Y925 FAK and anti-DAB2 antibodies revealed that
FAK phosphorylation on Y925 was localized at the tips of cel-
lular protrusions and it was strongly increased in DAB2shRNA unr shRNA D22 shRNA D47
N
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C
Fig. 4. FAK phosphorylation at Y925 by means of activated c-Src
aﬀects tube formation in endothelial cells. HUVEC were infected with
a lentiviral vector expressing unrelated (unr) or DAB2 shRNA clone
22 (D22) and clone 47 (D47). (A) Infected HUVEC were serum-
starved for 16 h with or without the presence of 2 lM Src kinase
inhibitor PP2. Cell extracts were immunoprecipitated using anti-
phospho-Y925 FAK (P-Y925) antibodies and the immunoprecipita-
tion was analyzed by Western blotting with anti-FAK antibodies
(FAK). To conﬁrm equal loading, whole cell lysates were analyzed by
Western blotting with anti-FAK and anti-b-actin antibodies. (B)
Infected HUVEC were mixed and plated on glass coverslips to obtain
in the same microscope ﬁeld cells expressing or not DAB2 protein.
Cells were grown in serum-deprived medium and analyzed by
immunoﬂuorescence using anti-DAB2 (DAB2) and anti-phospho-
Y925 FAK antibodies (P-Y925 FAK). A representative microscope
ﬁeld is shown and a white line indicates the cell border. Tlic,
transmitted light interference contrast of stained cells. Scale bar,
18 lm. (C) Infected HUVEC were grown on Matrigel in the presence
or not of 2 lM c-Src kinase inhibitor PP2 and the formation of
capillary-like structures was observed 20 h after seeding. A represen-
tative experiment is shown (·40 magniﬁcation). Results were expressed
as means ± S.E. of at least four independent experiments each in
triplicate.
2546 M. Orlandini et al. / FEBS Letters 582 (2008) 2542–2548silenced cells compared to the control (Fig. 4B). To demon-
strate the involvement of Src in DAB2-dependent activation
of FAK tyrosine phosphorylation, quiescent HUVEC were cul-
tured in the presence of 2 lM PP2, a selective Src inhibitor.
Immunoprecipitation analysis showed that in DAB2 silenced
endothelial the levels of Y925 FAK phosphorylation was de-
creased by PP2 treatment (Fig. 4A, lanes 4–6). Importantly,
tubulogenesis assays demonstrated that in the presence of
PP2 DAB2 silenced HUVEC were able to gather into clumps
and form the intricate tubular networks seen with control cells.
Of note, PP2 treatment per se did not alter the ability of control
cells to form tubular structures. Thus, PP2 treatment restored
in DAB2 silenced cells the ability to form capillary-like struc-B
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Fig. 5. Inhibition of DAB2 expression aﬀects MAPK signal transduc-
tion and enhances cell survival and proliferation in human endothelial
cells. HUVEC were infected with a lentiviral vector expressing
unrelated (unr) or DAB2 shRNA clone 22 (D22) and clone 47
(D47). (A) To investigate the activation status of the MAPK family,
infected cells were serum-starved for 18 h and cell extracts were
analyzed by Western blotting using anti-phospho-MAPK family (P-
MAPK) and anti-MAPK family (MAPK) antibodies to conﬁrm equal
loading. (B) Eﬀect of DAB2 knockdown on number of HUVEC
growing in complete culture medium. 2 · 104 cells were seeded and
MTT assays were performed at the times indicated. To estimate cell
number, the OD values of MTT were plotted on linear curves obtained
from known amounts of cells (see Materials and Methods). (C) Eﬀect
of DAB2 silencing on HUVEC growing in serum-depleted medium
(M199 culture medium containing 0.25% bovine serum albumin). At
the times indicated, MTT assays were performed and the ratios of the
absorbance of viable cells relative to initial seeded cells were expressed
as cell viability percentage. (D) Cell proliferation expressed as
thymidine uptake in infected or non-infected () HUVEC growing
in growth factor-free culture medium for 36 h. (E) The eﬀect of DAB2
silencing on survival of infected HUVEC growing in growth factor-
depleted culture medium for 20 h. The apoptotic percentage is the sum
of early, intermediate, and late apoptotic cells as shown in supple-
mentary data (Fig. S1C). All presented data were expressed as
means ± S.E. of 3–5 independent experiments, each in triplicate.tures in vitro. The above results demonstrate that DAB2, con-
trolling Src activation, regulates FAK, which is responsible of
the adhesion properties and the in vitro angiogenic cellular re-
sponses of human endothelial cells.
3.4. DAB2 aﬀects MAPK signaling, endothelial cell viability and
proliferation
Since Y925 in FAK is involved in intra- and inter-molecular
signalling crosstalk and activation of downstream pathways
[28], we next examined the impact of DAB2 knockdown on
the activation status of the MAPK family, ERK-1/2, JNK
and p38 serine/threonine protein kinases that are involved in
proliferation and migration of endothelial cells. As expected,
in growth factor-depleted conditions, control endothelial cells
did not show ERK phosphorylation. Conversely, quiescent
endothelial cells silenced for DAB2 showed a strong ERK-1/
2 stimulation respect to control cells (Fig. 5A). ERK phos-
phorylation was sustained, because it could be revealed at dif-
ferent time points during starvation (data not shown). A
similar proﬁle was also observed for JNK phosphorylation
while we observed a strong reduction of p38 phosphorylation
in DAB2 silenced cells. These results suggested an involvement
of DAB2 in endothelial cell viability and proliferation. There-
fore, we investigated the eﬀect of DAB2 silencing in HUVEC
by proliferation and survival assays. The number of viable cells
was estimated at diﬀerent time points of culturing. Cells
expressing DAB2 shRNA grown in complete growth medium
did not show any variation in cell number respect to cells in-
fected with control shRNA (Fig. 5B). However, when cells
were grown in growth factor-depleted medium, we observed
in control cells a strong decrease in cell viability, while in
DAB2 silenced cells viability was reduced for only 25% even
after 48 h of starvation (Fig. 5C). DNA synthesis, determined
in growth factor-depleted cells by thymidine uptake, was in-
creased in endothelial cells expressing DAB2 shRNA com-
pared to control cells (Fig. 5D). Moreover, ﬂow cytometric
assays with annexin V/propidium iodide double staining
showed that, in growth factor-depleted conditions, apoptosis
was reduced in endothelial cells expressing DAB2 shRNA re-
spect to the control (Fig. 5E). Taken together these results
demonstrate that in human endothelial cells, DAB2 depletion
aﬀects MAPK family activity and this change has diﬀerent ef-
fects on cell behavior.4. Discussion
During angiogenesis endothelial cells, in response to growth
factor stimulation, proliferate, migrate, and aggregate in a
coordinated process involving formation and disassembly of
cell adhesion sites to form vessels structures [24]. In this report
we analyzed the function of the adaptor protein DAB2 in hu-
man endothelial cells. By immunoﬂuorescence and Western
blotting we showed that DAB2 is highly expressed in human
endothelium and by RNA interference technology we observed
that DAB2 down-regulation aﬀects endothelial cell functions
crucial to angiogenesis like cell proliferation, survival, migra-
tion, and the alignment of endothelial cells in capillary-like
structures. These in vitro results contrast with Dab2 knock
out, which did not show vasculogenic defects. This discrepancy
could be explained by gene compensations in the knock-out
animals, as observed with other genes [30].
M. Orlandini et al. / FEBS Letters 582 (2008) 2542–2548 2547DAB2 is a putative tumor suppressor. It is downregulated in
various types of tumor and is capable of strongly inhibiting cell
growth and proliferation in many cell types [31–33]. In normal
and malignant prostatic epithelial cells, DAB2 is a negative
regulator of c-Src and the downstream Erk activation
[13,27]. Accordingly, we observed that in endothelial cells
DAB2 forms a complex with Src and that DAB2 depletion in-
creased Src activity, which was associated with peripheral
adhesions. At focal adhesions the integrin cytoplasmic do-
mains bind to a protein complex including Src and FAK.
These signaling molecules act to control focal contact turnover
during cell motility, although the molecular mechanisms are
only partly understood [34]. FAK has been shown to trigger
several downstream signaling pathways which mediate diﬀer-
ent phenotypes including cell spreading, growth, and survival
[34,35]. As FAK phosphorylation at Y925 is linked to adhe-
sion turnover [29,36], we analyzed the activation of FAK in
endothelial cells. We found that DAB2 knockdown induced
Y925 FAK phosphorylation and that in DAB2 silenced HU-
VEC the ability to form capillary-like tube structures was re-
stored after pharmacological inhibition of Src by PP2. These
results suggest that DAB2 controls migration and capillary-
like tube formation by modulating FAK activity via Src. Sus-
tained activation of Src-FAK signaling, as a result of DAB2
depletion, might increase the maturation of focal complexes
to stabilize focal adhesions or slowdown their turnover, result-
ing in inhibition of endothelial cell migration, which is a coor-
dinated process involving formation and disassembly of cell
adhesion sites.
We observed that in DAB2 silenced endothelial cells FAK
activation correlates with ERK and JNK phosphorylation.
These results are consistent with previous studies that Y925
FAK phosphorylation is important in promoting ERK and
JNK activity [28,36]. The regulation of these signaling path-
ways explains the observed increases in cell proliferation
and survival following DAB2 knockdown. Moreover, we
found that DAB2 silenced endothelial cells showed a balance
of MAPK activities, with inhibition of p38 activation con-
comitant with an increase of ERK phosphorylation. These re-
sults might explain the dual eﬀect of DAB2 knockdown,
which is responsible for the increased proliferation and sur-
vival together with inhibition of cell motility and tube forma-
tion. In conclusion, our results suggest that DAB2 exerts
its function as a signaling mediator in the control of endothe-
lial cell functions by modulating FAK and its downstream
signaling.
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